Kodu・Aktsiate loetelu・Moderna Inc

Moderna Inc

Suletud

SektorTervishoid

56.94 3.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

55.11

Max

58.19

Põhinäitajad
By Trading Economics
Sissetulek	561M -782M
Müük	-244M 145M
Aktsiakasum	-1.97
Kasumimarginaal	-539.31
Töötajad	4,700
EBITDA	554M -704M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-11.28% downside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-194M 22B
Eelmine avamishind	53.62
Eelmine sulgemishind	56.94

Uudiste sentiment

By Acuity

29%

71%

110 / 340 Pingereas Healthcare

Moderna Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3. aug 2026, 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31. juuli 2026, 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30. juuli 2026, 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29. juuli 2026, 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28. juuli 2026, 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27. juuli 2026, 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24. juuli 2026, 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23. juuli 2026, 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21. juuli 2026, 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20. juuli 2026, 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Võrdlus sarnastega

Hinnamuutus

Moderna Inc Prognoos

Hinnasiht

By TipRanks

-11.28% langus

12 kuu keskmine prognoos

Keskmine 48.92 USD -11.28%

Kõrge 77 USD

Madal 39 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Moderna Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Moderna Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

110 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.